Printer-friendly versionPrinter-friendly version

VHPB launches report on Innovative Financing into Hep B and C Prevention and Treatment.

Download the Press realease & Infographic

VHPB launches a report that reviews over 20 different existing funding mechanisms and examines how these financing sources could be used to support government strategies to provide access to treatment to patients suffering from viral hepatitis in low-and middle-income countries (LMICs). The purpose of the report is to increase understanding of the challenges and opportunities for LMICs of working with stakeholders in this new area of financing. The report was commissioned by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).Click here to download the full report.This report was written by Pierre Van Damme, Daniel Lavanchy, Greet Hendrickx, Ina Lodewyckx and Alex Vorsters (VHPB) in collaboration with Rob Walton, Michael Smith and Nina Lenton (Wisper Public Affairs) and was funded by the IFPMA member companies.

Eliminating a ‘silent killer’: innovative sources of financing to help meet costs of prevention and treatment of viral hepatitis, blog Pierre Van Damme

Tags: